ripekg:evaluation/RIPEA62FEC5B159F50CEC |
prov:used |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:concerns |
ripekg:work/10.1016%2Fj.eururo.2013.04.001OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:recruitmentEndDateExtractionRationale |
No explicit end-of-recruitment date after full search; range end is not used for recruitment_finish. |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:recruitmentStartDate |
10-2009 |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:recruitmentStartDateExtractionRationale |
Methods: 'This large, phase 3...study was conducted from October 2009 to August 2011...'; no specific FPI date found, using start of conducted range as recruitment_start per rule 5. |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:studyEndDate |
08-2011 |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
ripe:studyEndDateExtractionRationale |
Methods: 'This large, phase 3...study was conducted from October 2009 to August 2011...'; no specific completion date, using end of conducted range as study_end_date per rule 5. |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-2-2 |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-2-2 |